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Summary 
 
The SLC10A transporter gene family consists of seven members and substrates transported by 
three members (SLC10A1, SLC10A2 and SLC10A6) are Na+-dependent.  SLC10A1 (sodium 
taurocholate cotransporting polypeptide or NTCP) and SLC10A2 (apical sodium-dependent 
bile salt transporter or ASBT) transport bile salts and play an important role in maintaining 
enterohepatic circulation of bile salts. Solutes other than bile salts are also transported by 
NTCP. However, ASBT has not been shown to be a transporter for non-bile salt substrates. 
While the transport function of NTCP can potentially be used as liver function test, 
interpretation of such a test may be complicated by altered expression of NTCP in diseases 
and presence of drugs that may inhibit NTCP function. Transport of bile salts by NTCP and 
ASBT is inhibited by a number of drugs and it appears that ASBT is more permissive to drug 
inhibition than NTCP. The clinical significance of this inhibition in drug disposition and drug-
drug interaction remains to be determined. Both NCTP and ASBT undergo post-translational 
regulations that involve phosphorylation/dephosphorylation, translocation to and retrieval 
from the plasma membrane and degradation by the ubiquitin-proteasome system. These 
posttranslational regulations are mediated via signaling pathways involving cAMP, calcium, 
nitric oxide, phosphoinositide-3-kinase (PI3K), protein kinase C (PKC) and protein 
phosphatases. There appears to be species difference in the regulation of plasma membrane 
localization of human NTCP and rodent Ntcp. NTCP has recently been shown to play an 
important role in HBV and HDV infection by serving as a receptor for entry of these viruses 
into hepatocytes.  
    
Introduction 
 
Currently, the SLC10A gene family consists of seven members (30,41). Sodium-dependent 
bile salt transport in rat hepatocytes was first reported in 1978 (6). The transporter was first 
cloned from rat using a functional expression cloning approach (61,64) and is known as the 
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sodium taurocholate cotransporting polypeptide (Ntcp). It is the founding member of this 
family and is named Slc10a1 (59). Other members of the family include apical bile salt 
transporter (ASBT; SLC10A2), SLC10A3, SLC10A4, SLC10A5, Na+-dependent organic anion 
transporter (SOAT; SLC10A6) and SLC10A7 (30,41,50).  NTCP is localized at the basolateral 
membrane of hepatocytes, while ASBT is localized at the apical membrane of cholangiocytes, 
ileum and renal proximal tubules (32,41). SOAT transports sulfated taurolithocholate and 
sulfated steroid metabolites (34). Neither transport activity nor specific substrates have been 
identified for the gene products of SLC10A3, SLC10A4, SLC10A5 and SLC10a7 and these are 
currently considered orphan transporters. Of the seven members of the SLC10A family, NTCP 
and ASBT have been extensively characterized with established role in the enterohepatic 
circulation of bile salts.   
 
Bile salts are the major constituents of bile and play an important role in the intestinal 
digestion of fat and absorption of fat soluble vitamins (75). They may also play an important 
role in systemic energy homeostasis (123). Bile acids are synthesized in hepatocytes from 
cholesterol in a complex series of biochemical reactions (129). The resulting primary bile 
acids, cholic acid and chenodeoxycholic acid, are conjugated to glycine or to taurine (75). 
These conjugated bile salts have lower pKa values and are  consequently more hydrophilic 
and less cytotoxic than their unconjugated forms  (75). Inborn errors of bile acid biosynthesis 
can cause severe liver diseases (31,71,143). In hepatocytes, the newly synthesized bile salts 
mix with bile salts entering the cells via the basolateral membrane and are exported against a 
steep concentration gradient into the canaliculus. The canaliculi are the starting point of the 
biliary tree from where bile salts reach the duodenum to assist fat digestion. Bile salts are 
reabsorbed along the small intestine and transported via the portal circulation back to the liver 
for uptake and resecretion (76). This circling of bile salts is called enterohepatic circulation 
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and bile salts can be used as a model for understanding the journey of drugs undergoing 
enterohepatic circulation (36,77,148). 
 
NTCP and ASBT are the two members of the SCLC10 transporter family involved in 
maintaining uninterrupted enterohepatic circulation of bile salts.  Uptake of bile salts into the 
hepatocytes occurs predominantly by NTCP (SLC10A1) and to a lesser extent by OATPs 
(SLCOs) (105,146). So far, no inherited severe diseases associated with these transporters 
have been reported. Export of bile salts across the canalicular membrane is mediated by the 
ATP-dependent canalicular bile salt export pump BSEP (ABCB11) (105,146). Mutations in 
this transporter lead to progressive familial intrahepatic cholestasis type 2 suggesting a lack of 
backup transporter(s) for canalicular efflux of bile salts (80,92). Uptake across the apical 
membrane of enterocytes is mediated by the apical bile salt transporter ASBT (SLC10A2) 
(34,36), while the efflux from enterocyte at the basolateral membrane is facilitated by the 
heterodimeric transporter OST/OST  (35,36). Mutations in the gene coding for ASBT may 
lead to primary bile acid malabsorption (7). During the passage through the bile duct, a small 
fraction of bile salts undergoes reabsorption through cholangiocytes into the portal blood by 
transporters located at the luminal side (ASBT) and the basolateral side (MRP3/4 and 
OST/) and then into the hepatocytes by NTCP. This cycling of bile salts between 
cholangiocytes and hepatocytes is known as cholehepatic shunting (30,75). 
   
This review will focus on NTCP and ASBT highlighting latest developments and post-
translational regulations. Aspects of NTCP and ASBT not included in this review can be 
found in a number of excellent recent reviews on the family of SLC10A transporters 
(30,34,41,50,65,88). 
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2. Transport function of NTCP 
 
Ntcp is the only hepatocellular sodium-dependent uptake system for bile salts, at least in rats 
if not in all mammals and this is based on results that an Ntcp-specific antisense 
oligonucleotide co-injected with total rat liver mRNA into Xenopus laevis oocytes blocked the 
expression of Na+-dependent taurocholate (TC) uptake by approx. 95% (62). To date, no 
information on mice with a disrupted Slc10a1 gene has been published, which would allow to 
further support this previous finding. Also, in humans so far no patients with mutations 
rendering the transport activity of NTCP non-functional have been published. Hence, a 
definitive answer on the number of sodium dependent transport system(s) for uptake of bile 
salts into hepatocytes is still lacking. 
 
From a thermodynamic point of view, NTCP is a typical secondary active transporter and has 
been shown to be strictly sodium-dependent. NTCP necessitates the binding of two sodium-
ions together with a bile salt molecule for the transport step. In the case of the monoanionic 
TC, as well as the monoanionic fluorescent bile salt cholyl-N-NBD-lysine, Ntcp transport 
activity has been shown to be electrogenic, while it is electroneutral for the dianionic 
fluorescent bile salt cholylglycylamidofluorescein (164). Hence, depending on the charge of 
the substrate, the driving force of the uptake may vary and may consist of the energy available 
from the chemical and/or  the electrochemical gradient of sodium. 
 
The list of substrates transported by NTCP has been extensively reviewed (30,41,146). 
Solutes other than bile salts including steroid hormones, thyroid hormones, drugs  and drugs 
conjugated with bile acids can be transported by human/rat NTCP/Ntcp (SLC10A1/Slc10a1) 
(41,44). Comparison of published Km values for bile salts obtained from intact livers and 
heterologously expressed NTCP/Ntcp (41,146) suggests that the properties of the cloned 
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NTCP/Ntcp reflect reasonably well the affinity of NTCP/Ntcp in in-vivo situations. A study 
reported that hepatocellular carcinomas express NTCP, which mediates high-affinity uptake 
of chlorambucil-taurocholate (94). Thus, cytotoxic drugs conjugated with TC could provide a 
potential therapeutic strategy to deliver these drugs to hepatocellular carcinomas.  
 
In addition to endogenous substrates, drugs including statins and recently micafungin (170), 
an antifungal agent, have been reported to be transported by NTCP (41). Interestingly, 
rosuvastatin is transported by NTCP, but not by rat Ntcp (73). This is one example, which 
demonstrates that despite a large substrate overlap between rat, mouse and human NTCP 
(146) transport data should be extrapolated with caution across different species.   
 
The physiological relevance of a transporter is raised when a solute is transported by multiple 
transporters. For example, statins are also transported by organic anion transporting 
polypeptides (OATPs) (117) and this may also be true for other solutes not yet described. 
While the question of the physiologically relevant transporter(s) for drugs cannot be answered 
now, limited information is available for bile acids and bile salts as endogenous substrates. 
Upon heterologous expression of NTCP/Ntcp, this transporter is capable of transporting 
conjugated bile salts as well as e unconjugated bile acids (146). The same is observed for 
OATPs/Oatps expressed in liver with a preference for unconjugated bile acids (63). Thus, one 
could conclude that NTCP might, with respect to bile salt transport, replace hepatocellular 
OATPs. However and interestingly, mice with an inactivated locus for the Slco1a/1b 
subfamily display normal serum levels of conjugated bile salts, but have 13-fold elevated 
levels of unconjugated bile acids (157). Knocking out only Slco1b2 in mice also leads to some 
elevation of unconjugated bile acids with normal bile salt levels in serum (33). These findings 
suggest that, at least in mice, Ntcp is a very poor, if at all a transporter, for unconjugated bile 
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acids. In order to address the issue on transporter overlap for conjugated bile salts, data from 
Slc10a1 knock-out mice would be needed. 
 
The structure of NTCP has not yet been resolved. The current knowledge derived from 
modeling and mutation experiments is still very limited and summarized elsewhere (30,41). In 
cases where exact structural information is lacking, chemical modifications of substrates with 
subsequent transport/inhibition studies may yield further information on transport properties. 
To this end, the side chain of bile salts was identified as very important for substrate 
interaction with NTCP (9). Later, it was found by using a series of bile acids analogs with 
modifications at the C-3 and C-7 position that modifications at the C-7 but not at the C-3 
position abolished NTCP mediated transport with comparable results for ASBT (87). Two 
recent studies reported on a pharmacophore model and a structure-activity relationship for 
NTCP, respectively (40,55). The first study (55) identified two hydrogen bond acceptors and 
three hydrophobic elements as important structural features. Thereby the distance between the 
hydrogen bond acceptor features as well as the presences of one or two negative charges 
(absent in their features) are essential for successful interaction of compounds with NTCP. 
The second study (40) used inhibition studies with drugs and found that two hydrophobic 
elements and one hydrogen bond acceptor are of importance for the interaction with NTCP. 
Hence, the two models show considerable differences. One reason  could be the use of IC50 
values for model development. IC50 values give no information on the type of inhibition (23) 
and hence may include substance binding distant to the substrate binding site of NTCP. 
 
3. Transport function of ASBT 
 
Different from NTCP, the substrate specificity of ASBT is considerably narrower. 
Traditionally, bile acids and bile salts were identified as sole ASBT substrates (34,41). Lately, 
evidence has been presented supporting the concept that bile salt transport capacity of ASBT 
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is phylogenetically conserved (101). Interestingly, a bacterial homologue of ASBT is also 
capable of mediating bile salt transport (78). New studies have expanded the list of substrates 
to two uncharged non-bile salt substrates containing an amide bond and an alcohol expanding 
the substrate spectrum of ASBT to solutes other than bile salts (87). ASBT has been proposed 
to be used as target for mediating intestinal absorption of drugs conjugated to bile salts to 
increase the bioavailability of such drugs. This "Trojan horse" approach has, however, met 
with limited success (8). This observation further supports the concept of ASBT having a 
rather narrow substrate specificity. Mechanistically, ASBT is electrogenic requiring 
cotransport of two sodium ions together with a bile salt molecule (34).  
 
The structure of a mammalian ASBT has not yet been determined. However, recently a 
crystal structure of ASBT from Neisseria meningitis was elucidated at 2.2 Å. ASBTNM from 
N. meningitis is 26 % identical and 54 % similar to human ASBT and transports TC in a 
sodium-dependent manner with a Km-value of 52 M (78).  This structure, obtained in the 
presence of TC and sodium, revealed 10 transmembrane domains and a hydrophobic inward-
facing binding cavity. This bacterial ASBT structure differs considerably from the currently 
favored model for mammalian ASBT thought to cross the plasma membrane 7 to 9 times 
(30,41). Hence, clearly much more work is needed to understand the structure of mammalian 
ASBT.  
 
As ASBT is a candidate for enhancing intestinal absorption of (pro)drugs, extensive structure 
function studies aimed at determining a pharmacophore structure for ASBT substrates have 
been conducted. Based on functional studies using intestinal perfusion and everted intestine 
sac models, several requirements for ASBT substrates were found to be important (34) and 
these include a negatively charged side chain, at least one hydroxyl group at the steroid 
nucleus position 3, 7 or 12 and a cis-configuration of the steroid backbone.  Extensive further 
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studies led to the development of a first pharmacophore model, which differed considerably 
from the early model. This model consists of a hydrogen bond donor function, a hydrogen 
bond acceptor function and three hydrophobic features. Importantly, neither the 3-
hydroxygroup of the steroid ring nor a cis-orientation of the A-ring was found to be important 
(9). The current state of knowledge on the chemical properties of ASBT substrates shows the 
following main features (87,90): 1) binding of a bile salt to ASBT involves one hydrogen 
bond donor, one hydrogen bond acceptor and three hydrophobic interactions, 2) lack of a 
negatively charged C-24 side chain maintains some affinity for ASBT, but the negatively 
charged side chain is necessary for high affinity and 3) the 3-position is the preferred position 
for drug targeting to ASBT. 
 
4. Role of NTCP in Liver function tests: 
 
Anionic dyes have been known to be extracted from blood by the liver and that some of them 
may undergo enterohepatic circulation has been known for more than 100 years (1). 
Bromosulfophthalein (BSP) and indocyanine green (ICG) have been used clinically, whereby 
the latter is still in use today (131). BSP was indeed the substrate used when the first Oatp (rat 
Oatp1a1) was identified by expression cloning (81). Today, the role of transport systems in 
liver function tests is increasingly appreciated (74,147). Rat Ntcp was found to transport BSP 
if expressed in Xenopus laevis oocytes (60) and displayed a Km for BSP of 3.7 M when 
stably expressed in HeLa cells (68). Also human NTCP transports BSP (43) and in addition 
mediates uptake of ICG into stably transfected cells (37). A comparative study (97) using the 
three heptaocellular OATPs and NTCP found that NTCP can mediate uptake, albeit weakly, 
of the magnetic resonance imaging contrast agent gadolinium-ethoxybenzyl-
diethylenetriamine pentaacetic acid (Gd-EOB-DTPA). Hence several exogenous compounds 
used to assess dynamic liver functions in humans are (among other transporters) taken up by 
NTCP into human hepatocytes. Naturally, endogenous substrates are a viable option for 
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dynamically assessing liver function, as there will be no issues related to potential toxicity, as 
for example for BSP (131). Indeed, radioactively labeled cholylglycine shows a decreased 
clearance in patients with liver disease in comparison to healthy controls (96). In addition, 
there is a good correlation between clearances of cholyltaurine and ICG (119). Instead of 
using radioactively labeled bile salts, fluorescent bile salts could potentially be an alternative, 
given that NTCP does not exclusively transport bile salts. A pilot study in a small number of 
patients with liver cirrhosis proved this concept for cholyl-lysyl-fluorescein (CLF) (108). An 
investigation of CLF as potential substrate for organic anion transporters present in 
hepatocytes did however demonstrate that CLF is not a substrate for NTCP, but rather for 
OATP1B3 and to a lesser extent for OATP1B1 (38). The same study however found that CLF 
is a very good inhibitor of NTCP. This exemplifies that the modifications of NTCP substrates 
have to be carefully considered and support the concept that the side chain of bile salts is a 
critical determinant for their recognition by NTCP as a transported substrate (9). The 
following fluorescent bile salts have been shown to be substrates of rat or human NTCP: 
cholylglycylfluorescein and chenodeoxycholyllysyl-NBD (22), NBD-cholyltaurine (122), 
cholylglycylamidofluorescein and chenodeoxycholylglycylamidofluorescein (109,114). 
 
The fact that several substances used to perform dynamic liver function tests are transported 
by NTCP has several implications: 1. The sodium-gradient across the plasma membrane 
constitutes a driving force for NTCP. This sodium gradient is maintained by (Na+, K+)-
ATPase. In some forms of liver diseases, the activity of (Na+, K+)-ATPase may be impaired as 
shown  in an animal model of endotoxin-induced cholestasis (156). Also, treatment of rats 
with pharmacologic doses of ethinylestradiol has been found by some to reduce the activity of 
(Na+, K+)-ATPase (11,107) but not by others (17,18,95) 2. NTCP expression can be up or 
down regulated in certain forms of human liver diseases. Thus, NTCP is down-regulated in 
progressive familial intrahepatic cholestasis (84), inflammatory cholestasis, primary biliary 
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cirrhosis and chronic hepatitis C (67,115,173,174), while NTCP is up-regulated in 
nonalcoholic steatohepatitis (10), end-stage primary biliary cirrhosis (153) and in patients 
with late-stage obstructive cholestasis (25). 3. Polymorphic variants of the SLC10A1 gene 
lead to the expression of NTCPs with different transport properties (72). 4. mRNA expression 
of NTCP is subject to considerable inter-individual variability (85) and may translate into 
variable protein expression as demonstrated for hepatocellular ABC-transporters (106). 5. 
Certain drugs may interfere with the transport activity of NTCP. Hence, while some liver 
function tests may be affected by a disease and patient dependent altered expression and/or 
function of NTCP, clearly more information is needed to take advantage of NTCP as a 
molecular determinant in dynamic liver function tests. 
 
5. Clinical implication of inhibition of NTCP/ASBT by drugs 
 
 
Drugs may inhibit solute transport by NTCP/ASBT in two major ways: 1) drugs may be 
transported by the transporters resulting in competitive inhibition and 2) drugs may inhibit 
solute uptake by the transporters without being transported by the transporter. Indeed, there 
are drugs that inhibit NTCP/Ntcp mediated bile salt uptake, but are not transported by 
NTCP/Ntcp (41,89,146).  Drugs that inhibit solute transport by transporters with or without 
being transported can have significant effects on the disposition of endogenous substrates and 
drugs. These effects are important considerations in drug development, as they may result in 
adverse effects or provide therapeutic strategies. Thus, inhibition of NTCP would be expected 
to impair disposition of bile salts resulting in higher systemic concentration of bile salts and 
consequent adverse effects (103,109). Similarly, inhibition of ASBT will result in disruption 
of enterohepatic circulation of bile salts and increased fecal loss of bile salts and their 
metabolites resulting in undesirable  effects of bile acids in the colon, such as diarrhea (124). 
Inhibition of ASBT also results in effects secondary to decreased intestinal bile acid 
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absorption, such as decreased plasma cholesterol (100). Thus, an experimental drug (SC-435) 
inhibits TC uptake by ASBT and reduces atherosclerosis in apolipoprotein E null mice (14). 
In addition, inhibitors of ASBT (A3309 & 264W94) have been shown to produce beneficial 
effects in patients with chronic idiopathic constipation (27,144) and alleviate diabetes in 
Zucker Diabetic Fatty (ZDF) rats (26).  A number of drugs have been shown to inhibit ABST 
(40,54,172) and these include calcium channel blockers (nifedipine, isradipine, diltiazem, 
verapamil), HMG-CoA reductase inhibitors (simvastatin, mevastatin, lovastatin), diuretics 
(spironolactone, bumetadine, althazide, but not furosemide) and others (dibucaine, 
indomethacin, mesoridazine, quinine). However, the clinical implications of inhibition of 
ASBT by these drugs are yet to be determined.  
 
The effect on drug disposition can also lead to drug-drug interaction (DDI). DDI is an 
important determinant of drug safety and efficacy, and is influenced by factors that affect drug 
disposition.  It is becoming evident that transporters often work together with drug 
metabolizing enzymes in drug disposition. While interactions with drug metabolizing 
enzymes have long been considered to be important in drug disposition, a role for transporters 
in drug disposition, therapeutic efficacy and adverse drug reactions has increasingly been 
recognized (90). Some transporters are considered to be clinically important in drug 
absorption and disposition and therefore could mediate DDIs (51). Although a number of SLC 
transporters are considered to have clinical importance in the absorption and disposition of 
drugs (51), NTCP and ASBT are not included. This is mainly because the clinical importance 
of these transporters is not well established. Since drugs can be transported by NTCP and can 
also inhibit solute transport by NTCP, a potential role of NTCP in drug-drug interaction is 
very likely and is reported (69,170).  Similarly, ASBT may also be involved in drug-drug 
interactions that may be revealed in future studies.  
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There appears to be a difference in the ability of drugs to inhibit NTCP and ASBT. A 
previous study in rabbit suggested that more drugs inhibited Ntcp than Asbt (91).  A recent 
study compared the inhibitory potentials of a number of FDA approved drugs for NTCP and 
ASBT (40). This study identified 27 drugs as novel NTCP inhibitors, including a variety of 
therapeutic classes including antifungal, antihyperlipidemic, antihypertensive, anti-
inflammatory, and glucocorticoid drugs. Of the 72 drugs tested, a total of 31 drugs inhibited 
NTCP, while 51 drugs inhibited ASBT with overlapping inhibition.  These results suggest 
that ASBT is more permissive to drug inhibition than NTCP and this may be related to NTCP 
possessing fewer pharmacophore features.  Whether the differences in the permissiveness to 
drug inhibition between the two transporters are due to species difference remains to be 
established. The possibility of species differences is consistent with the findings that 
rosuvastatin is a human NTCP substrate but not a substrate for rat Ntcp (73) and bosentan is a 
more potent inhibitor for rat Ntcp than human NTCP (98).  
 
6. Post-Translational Regulation of NTCP/Ntcp and ASBT/Asbt  
 
Both NTCP and ASBT undergo transcriptional and post-transcriptional regulations. 
Transcriptional regulation involving various nuclear receptors has recently been reviewed by 
others (30,88) and hence the focus of this review will be post translational regulation. Plasma 
membrane transporters, after translation, need to be translocated to the plasma membrane to 
carry out their intended functions. The level of a transporter in the plasma membrane may be 
increased or decreased based on the need to regulate solute transport by the transporter. This 
is a highly regulated post-translational event requiring involvement of various cellular 
signaling pathways and is best exemplified by the regulation of glucose transporter (Glut4) by 
insulin in adipocytes and skeletal muscle (45,99). The post-translation event also involves 
protein quality control to select and target dysfunctional proteins for degradation by the 
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ubiquitin-proteasome system (29).  Studies to date suggest that the post-translational 
regulation of NTCP as well as ASBT involves plasma membrane transport/retrieval and 
degradation by the ubiquitin-proteasome system. Several signaling pathways have been 
implicated in the post-translational regulation of these transporters and these pathways include 
cAMP, intracellular Ca2+, nitric oxide, and activation of phosphoinositide-3-kinase (PI3K),  
proteins kinase Cs (PKCs) and protein phosphatases. The role of these pathways is better 
understood for NTCP (Fig. 1) than ASBT because of limited studies with ASBT. Some of 
these pathways have previously been reviewed (4,20,88).  
 
Plasma membrane level of NTCP and thereby hepatic TC uptake is regulated by cAMP and 
bile acids. Cyclic AMP stimulates TC uptake (19,57,118,139) and increases plasma 
membrane level of Ntcp/NTCP in rat hepatocytes and in hepatic cells stably transfected with 
human NTCP (42,111,139). In contrast, cholestatic bile salts (taurochenodeoxycholate 
(TCDC) and taurolithocholate (TLC)) inhibit TC uptake (110,142) and decrease plasma 
membrane Ntcp (110,141). Thus, bile salts uptake by NTCP/Ntcp undergoes dynamic 
regulation.  The increase in uptake by cAMP, increased by glucagon, may allow the 
hepatocytes to efficiently absorb bile salts returning from the intestine under physiological 
conditions, while the decrease in uptake may protect hepatocytes from further increases in 
intracellular bile salts observed in cholestasis (125). Functionally important polymorphisms in 
NTCP may result in decreased plasma expression.  Multiple single nucleotide polymorphisms 
in NTCP have been shown to be present in populations of European, African, Chinese, and 
Hispanic Americans, and the altered transport activity of Ile223 to Thr variant seen only in 
African Americans was due at least in part to decreased plasma membrane expression (72). 
 
A role of PI3K in bile formation is evident from a study (46) showing that wortmannin, a 
specific inhibitor of PI3K, inhibits bile formation, bile acid secretion and vesicle trafficking in 
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isolated perfused rat liver. Since then various studies have provided evidence supporting a 
role for PI3K/Akt pathway in cell survival and translocation of hepatocellular transporters to 
the plasma membrane, indicating a beneficial role of PI3K in hepatic cells (4,48,130,160). 
PI3Ks are a family of lipid kinases (classes I, II, and III) that phosphorylate the inositol ring 
of phosphatidylinositides (PIs) at 3 position known as D3 phosphorylation (24). The resulting 
phosphorylated PIs (PIPs), acting in concert with phosphoinositide-dependent kinases 
(PDKs), are involved in the activation of downstream kinases, such as PKC/, Akt/PKB, and 
p70S6K (154). The PI3K/Akt pathway  is involved in cell swelling and cAMP-induced 
increases in TC uptake and Ntcp translocation to the plasma membrane (159,163) and cAMP 
inhibits TLC-induced inhibition of TC uptake by activating the PI3K pathway (141). The 
effect of cAMP on Ntcp translocation is also mediated via PI3K/PKC (118,136) and 
PI3K/PKC (102) pathways (see below).   
 
Ntcp translocation to the plasma membrane is regulated by phosphorylation and 
dephosphorylation, although kinase(s) involved in phosphorylation of Ntcp has not yet been 
identified. NTCP is a serine/threonine phosphorylated protein (112) and cAMP-induced 
increases in TC uptake and plasma membrane Ntcp is associated with Ntcp dephosphorylation 
(113) at Ser226 (5). Cyclic AMP increases intracellular Ca2+ (57) and the ability of cAMP to 
dephosphorylate Ntcp is inhibited by a calcium chelator (112).  Cyclic AMP activates protein 
phosphatase 2B (PP2B), a Ca2+/calmodulin-dependent serine and threonine protein 
phosphatase (86) by increasing intracellular Ca2+ (161). PP2B directly dephosphorylates Ntcp 
and an inhibitor of PP2B inhibits cAMP-induced dephosphorylation and translocation of Ntcp 
(161). Taken together, these results suggest that cAMP activates PP2B by increasing 
intracellular Ca2+ and PP2B in turn dephosphorylates Ntcp facilitating its translocation to the 
plasma membrane (Fig. 1).  Interestingly, inhibition of PP2B has been shown to reverse 
TCDC-induced retrieval of Ntcp (110).  Whether TCDC-induced retrieval of Ntcp involves 
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PP2B mediated dephosphorylation of Ntcp remains to be established. It is however possible 
that inhibition of PP2B results in increased phosphorylation of a mediator that is involved in 
the retrieval of Ntcp.   
 
Cyclic AMP-dependent increases in apical ASBT in cholangiocytes (3) and rat ileum (128) 
have been reported. Secretin, acting via cAMP, increases apical ASBT in cholangiocytes, 
which is reversible and requires intact microtubules (3). This result suggests acute stimulation 
of vesicular translocation of ASBT to the apical membrane and this may explain secretin 
induced increased cholehepatic shunting and associated increases in the choleretic effect of 
bile acids (165). It does not appear that ASBT translocation is affected by phosphorylation. 
ASBT has not been shown to be phosphorylated. However, mutation of potential 
phosphorylation sites (S335 and T339) in the cytoplasmic tail of Asbt by non-
phosphorylatable alanine results in decreased initial bile acid transport activity and increases 
the basolateral distribution of the mutants without significantly decreasing apical distribution 
(152). Thus, phosphorylation, if it occurs, may inhibit basolateral targeting of ASBT in 
cholangiocytes.  
 
Like NTCP/Ntcp (93), Asbt in cholangiocytes undergoes degradation via the ubiquitin-
proteasome system (166). Ntcp/NTCP is shown to be degraded by the ubiquitin-proteasome 
system at the level of ER-associated degradation. It is speculated that dysfunction of this 
pathway may result in intracellular NTCP deposits in cholestatic livers (93).  Since mutation 
of S335 and T339 to alanine in Asbt reduces the rate of ASBT disposal under basal conditions 
as well as IL-1β -dependent ubiquitination and disposal of ASBT, it is suggested that Asbt 
degradation by proteasome involves phosphorylation followed by ubiquitination (166).   
However, role of phosphorylation has not been directly assessed.  
 
17 
 
Protein kinase C isoforms have been shown to mediate NTCP/Ntcp translocation to and 
retrieval from the plasma membrane (Fig. 1). Protein kinase C belongs to a family of 
serine/threonine protein kinases that are involved in the regulation of diverse cellular 
functions and consists of at least 12 isoforms (116,127). Activation of most PKCs, if not all, is 
PI3K dependent (116). PKCs shown to be present in rat hepatocytes include PKC, PKC, 
PKC, and PKC with the presence of PKCII being controversial. (13,83,149).  Initial 
studies with PMA, activator of conventional and novel PKCs, suggested that activation of 
PKCs inhibits TC uptake in hepatocytes (4,21,57). More recent studies suggest that TC uptake 
and NTCP translocation/retrieval are differentially affected by PKC isoforms. Thus, PKC 
(118,136) and PKC (102) mediate cAMP-induced NTCP/Ntcp translocation, while 
conventional PKCs (most likely PKC) mediate Ntcp retrieval (110,150). The activation of 
PKC and PKC by cAMP is PI3K-dependent (102,118,136), while TCDC-induced Ntcp 
retrieval is enhanced when PI3K is inhibited (110). Thus, it does not appear that TCDC-
induced activation of PKC is dependent on PI3K. On the other hand, TLC induces retrieval 
of Ntcp in rat hepatocytes (141), but inhibits PKCα (12). Thus, the retrieval of Ntcp by 
cholestatic bile acids may involve mediators in addition to PKC. TLC, which activates 
PKC in hepatocytes (13,141), also inhibits TC uptake in hepatocytes (142) and in HuH-
NTCP cell (141). However, TLC-induced inhibition of TC uptake is not mediated via PKC 
(141).  In contrast, TLC-induced retrieval of MRP2 is mediated via PKC (140). Thus, the 
canalicular membrane may be the target of PKC and this is consistent with the finding that 
TLC translocates PKC to the canalicular membrane (13). PMA, an activator of PKCs, has 
been shown to inhibit TC uptake and decrease plasma membrane ASBT in Caco-2 cells 
transfected with ileal ASBT (133). This effect of PMA appears to be mediated via PKC. It is 
speculated that this pathway may underlie the pathophysiology of diseases associated with 
disruptions in bile acid homeostasis.  
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There are limited studies exploring the mechanism by which PKCs affect NTCP translocation. 
These studies suggest a role for Rab4, a small GTPase, which cycles between GTP bound 
(Rab4-GTP) active form and GDP bound (Rab4-GDP) inactive form and is involved in 
endocytosis (2). Thus, PKC facilitates Ntcp translocation by activating Rab4 (118) and 
PKC increases motility of Ntcp containing vesicles along the microtubules (132). Other 
studies showed that Rab4 facilitates cAMP-induced Ntcp translocation (139), Ntcp containing 
vesicles co-localize with Rab4 (132), cAMP induced Ntcp translocation is dependent on PI3K 
dependent (162) and actin cytoskeleton and microtubules (42,162), and activation of PKC 
and PKC is PI3K dependent (102,118,136).  Taken together, these results may suggest that 
activation of PI3K/PKC by cAMP leads to activation of Rab4 in Ntcp containing Rab4 
vesicles and this is followed by PI3K/PKC mediated increased motility of Ntcp/Rab4 
containing vesicles along the microtubules to the plasma membrane (Fig. 2).  
 
Post translation modification affecting plasma membrane localization of NTCP also involves 
S-nitrosylation. Treatment with thiol-binding agents inhibits TC uptake in isolated rat 
hepatocytes (15,16) and by NTCP and ASBT (66) indicating a role for cysteine residues in 
transport function.  Nitric oxide has been shown to inhibit TC uptake in rat hepatocytes (145), 
HuH7 cells stably transfected with human NTCP (138) and human hepatocytes (53).  One of 
the ways that NO exerts its cellular effects is through a posttranslational modification termed 
S-nitrosylation, which involves binding of NO to reactive thiol groups on cysteine residues 
(70,135). A number of proteins (transcription factors, kinases, phosphatases, membrane 
receptors and transporters) are regulated by S-nitrosylation (39,70) and abnormal S-
nitrosylation of proteins has been implicated in a number of human diseases including sepsis, 
diabetes and cystic fibrosis (28,47,58,120,126,137). Human NTCP has four cysteine residues 
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(Cys44, Cys98, Cys125, and Cys266) that are conserved in rat, mouse, and rabbit (171). Thus, 
inhibition of TC uptake by NO may involve S-nitrosylation of NTCP. Indeed, NO has been 
shown to S-nitrosylate NTCP (53,138) and this is associated with a decrease in plasma 
membrane NTCP (138). Moreover, dithiothreitol reverses NO-mediated inhibition of TC 
uptake and S-nitrosylation of NTCP (138). A follow up study showed that the  inhibition of 
TC uptake by NO may involve S-nitrosylation of Ntcp-Cys96  (155). Such a mechanism may 
be involved in LPS-induced cholestasis, which is associated with a burst of NO production by 
iNOS in liver cells (49).  
 
NO also produces its cellular effects by nitration of tyrosine residues (79) and has been shown 
to increase tyrosine nitration of NTCP (53). However, the effect of tyrosine nitration on TC 
uptake and plasma membrane NTCP has not been directly studied.  It may be noted that two 
tyrosine residues on the cytoplasmic tail of rat NTCP appear to be involved in targeting to the 
basolateral membrane (151). Thus, it is possible that tyrosine nitration of NTCP by NO may 
also result in decreased translocation to the basolateral membrane resulting in decreased TC 
uptake.  
 
There appears to be species differences in the regulation of plasma membrane localization of 
NTCP and Ntcp. TLC inhibits TC uptake by NTCP and Ntcp. However, TLC decreases 
plasma membrane rat Ntcp but not human NTCP (141).   Like Bosentan (98), TLC inhibits 
TC uptake by Ntcp and NTCP non-competitively (142) and competitively (141), respectively. 
NO inhibits TC uptake by NTCP/Ntcp. However, NO decreases plasma membrane NTCP 
(138) and does not affect plasma membrane level of rat Ntcp (155).  In contrast, cAMP-
induced increases in TC uptake are associated with translocation of NTCP as well as Ntcp.  
These differences should be taken into account when extrapolating mechanisms regulating 
Ntcp to NTCP.  
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7. A novel function of NTCP: 
 
A novel function for NTCP as a receptor and transporter for hepatitis B virus (HBV) and 
hepatitis D virus (HDV) has recently been described (169). Both HBV and HDV contain three 
envelope proteins known as small (S), middle (M), and large (L). These proteins share the 
same C-terminal domain corresponding to the S protein, but differ at the N-terminal domains 
by the presence of pre-S2 domain in M protein and pre-S1 and pre-S2 domains in L protein. 
The entry of both HBV and HDV is determined by the pre-S1 domain of L protein after 
interacting with cellular receptor(s) on hepatocytes (52), as evidenced by inhibition of viral 
entry and infection by myristoylated N-terminal 47 amino acids of the pre-S1 domain of L 
protein (56,104). Myrcludex B, a drug based on myristoylated pre-S1 domain, has entered 
clinical trials after demonstration of efficacy against both HBV and HDV infection in an uPA-
SCID mouse model (121), indicating potential clinical significance of viral entry inhibition in 
the treatment of HBV/HDV.  Despite these advances, the identity of the receptor(s) remained 
elusive until the studies by Yan et al (169).   
 
In an elegant series of experiments Yan et al showed (169) that the receptor-binding region of 
pre-S1 domain of L protein specifically interacts with NTCP and amino acids 157 to 165 of 
NTCP (KGIVISLVL) are critical for viral entry.  A follow up study showed that mouse Ntcp 
can bind pre-S1 domain of HBV L protein, but does not support HBV or HDV infection 
(168).  However, substitution of mouse Ntcp residues 84 to 87 by human counterparts 
effectively supports viral infections. Thus, there may be multiple domains of NTCP involved 
in supporting viral infections. In addition, insensitive hepatic cell lines (HuH-7 and HepG-2) 
transfected with human NTCP supported HBV/HDV infection (168), although the extent of 
infection was much lower than in hepatocytes. Thus, human NTCP plays an important role in 
viral entry and consequent infection. However, viral entry is only one step in efficient viral 
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infection and replication in human hepatocytes and other factors, such as host components, 
are likely to be involved (134,158,167).  
 
These results raise interesting questions about the transport function of NTCP. One possibility 
may be that these viruses are transported by NTCP the same way as it transports bile salts. In 
that case, it would be important to know whether the transport of HBV and HDV into 
hepatocytes is Na+ dependent and is inhibited by known substrates/inhibitors of NTCP. It is 
however possible that this is a novel function of NTCP with molecular mechanism of the 
transport function is yet to be determined. A likely possibility is that NTCP is internalized by 
endocytosis following binding to the virus allowing the virus to enter the cell, as also 
suggested by others (158,167).   Internalization of HBV/HDV may be initiated by protein-
protein interactions between the envelop protein of the virus and NTCP leading to 
endocytosis. In that case, what would be the signal for internalization and how is that signal 
generated? Calcium dependent conventional PKCs and most likely PKC have been shown to 
induce Ntcp retrieval (110,150). Whether PKC or other signaling molecules may be 
involved remains to be investigated. Irrespective of the transport mechanism involved, the 
finding that NTCP is involved in HBV and HDV infection is expected to inspire further 
studies leading to a better understanding of the role of NTCP in HBV/HDV infection and 
development of agents to inhibit viral entry and infection.    
 
8. Future perspectives 
 
NTCP and ASBT were originally described to transport bile salts and play an important role 
in enterohepatic circulation of bile salts.   It is now apparent that these transporters are capable 
of transporting other solutes including drugs and viruses. The physiological and clinical 
relevance of NTCP for drugs transported by additional transporters requires further 
examination. The ability of drugs to be transported or to inhibit solute transport by these 
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transporters is likely to affect drug disposition resulting drug-drug interactions, provide 
strategies for novel drug development and alter disposition of endogenous substrates.  Further 
studies are needed to fully explore the clinical relevance of such interactions.  The ability of 
NTCP to transport HBV/HDV and thereby facilitate hepatic viral infection should lead to 
further studies providing better understanding of the transport mechanism and regulation of 
NTCP as well as mechanisms of and therapy against HBV/HVD infection. Further studies are 
needed to define the conditions and substrates for NTCP to be used for liver function tests.  
Our understanding of cellular mechanisms involved in the post-translational regulation of 
NTCP/ASBT has been steadily increasing. It is apparent that solute transport by these 
transporters is acutely regulated by translocation to and retrieval from the plasma membrane. 
However, signaling pathways involved are incompletely understood, especially for ileal 
ASBT.  A better understanding of the signaling pathways regulating plasma membrane 
localization should allow us to target specific pathways to limit or enhance solute transport 
and thereby limit hepatic toxicity or enhance hepatic functions as needed.  Most of the 
SLC10A transporters are considered to be orphan transporters and hence very little is known 
about the regulation of these orphan transporters. It is anticipated that substantial progress in 
these areas will be made in the near future.    
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Figure Legend 
 
Figure 1. Postulated signaling pathways regulating NTCP/Ntcp insertion into and retrieval 
from the plasma membrane. Cyclic AMP increases hepatic uptake of bile acid by increasing 
plasma membrane level of NTCP/Ntcp. The effect of cAMP is mediated via two major 
pathways; activation of PI3K and increase in intracellular Ca2+. Activation of PI3K leads to 
activations of Akt, PKC and PKC, which in turn induce translocation of NTCP/Ntcp from 
intracellular compartment to the plasma membrane most likely by stimulating vesicular 
trafficking of NTCP/Ntcp containing vesicles. Ntcp is a phosphoprotein and the 
dephosphorylated Ntcp undergoes translocation to the plasma membrane.  Increases in 
intracellular Ca2+ by cAMP leads to activation of Ca2+-dependent protein phosphatase 2B 
(PP2B) via Ca2+-calmodulin kinase (Ca2+-CAM). PP2B dephosphorylates Ntcp allowing 
translocation to the plasma membrane. On the other hand, activation of PKC by a cholestatic 
bile acid, taurochenodeoxycholate (TCDC), stimulates retrieval of Ntcp from the plasma 
membrane by an as yet unknown mechanism except that inhibition of PI3K and PP2B 
enhances the effect of TCDC.   
 
Figure 2. Postulated role of Rab4, PI3K/PKC and PI3K/PKC in the translocation of 
NTCP/Ntcp. Ntcp containing vesicles co-localize with Rab4, which cycles between GTP 
bound (Rab4-GTP) active form and GDP bound (Rab4-GDP) inactive form.    Activation of 
PKC leads to the conversion of inactive Rab4-GDP to active Rab4-GTP, which moves 
NTCP containing vesicles towards the plus end of microtubules (Mt) by interacting with 
kinesin-1. This movement is further facilitated by PKC.  
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